Why Sino Biopharmaceutical’s twin respiratory deals may worry global pharma rivals
Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China
